Interlaboratory variation in the detection of HPA-specific alloantibodies and in molecular HPA typing

被引:19
作者
Allen, D.
Ouwehand, W. H.
de Haas, M.
Kekomaki, R.
Kaplan, C.
Metcalfe, P.
机构
[1] Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England
[2] Natl Blood Serv, Oxford, England
[3] Univ Cambridge, Natl Blood Serv, Cambridge, England
[4] Sanquin Res, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, Amsterdam, Netherlands
[6] Finnish Red Cross & Blood Serv, Helsinki, Finland
[7] Natl Inst Blood Transfus, Paris, France
关键词
HPA antibodies; HPA genotyping; PCR-SSP;
D O I
10.1111/j.1423-0410.2007.00960.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives Platelet immunology quality assurance exercises have been organized by National Institute for Biological Standards and Control since 1991 and, as of 2006, 35 laboratories participate in the serology section. Molecular human platelet antigen (HPA) typing has been included in the exercises since 1998 and, as of 2006, 29 laboratories participate in this part of the exercise. This report details the performance of laboratories in these two areas. Materials and Methods Every 6 months laboratories are sent up to four coded serum/plasma samples for testing in their in-house assays for HPA antibody detection/identification and four coded whole blood samples to be typed for HPA-1, -2, -3 -5 and (since 2003) -15 by their molecular typing assays ('genotyping'). Results Fifty-two sera containing HPA-specific alloantibodies and 13 sera that were inert, contained only human leucocyte antigen (HLA) class I or high-titre anti-A+B antibodies were distributed; 15 sera were issued in more than one exercise. The percentage of participating laboratories that were able to detect HPA-specific alloantibodies ranged from 15 center dot 0 to 100%; the percentage that were able to correctly determine the specificities also ranged from 15 center dot 0 to 100%. Over the 20 serology exercises the percentage of laboratories classified as poor performers ranged from 3 center dot 1 to 36 center dot 7%. A total of 12 780 individual HPA genotyping results were assessed. The overall error rate was 0 center dot 7% but there was considerable variation between HPA alleles. Over 11 exercises the percentage of laboratories classified as poor performers varied from 6 center dot 3 to 26 center dot 3%. Conclusions The ability to detect and to identify platelet-specific alloantibodies varied widely between laboratories and between various examples of antibodies issued. An increase in the number of laboratories screening for HPA-15 antibodies was seen, although detection and identification of these antibodies was problematic. The majority of examples of HPA-3a antibodies and some examples of HPA-1a and -5b were also difficult to detect and identify. In addition, this scheme has shown that despite the apparent reliability of molecular typing techniques, mistakes do occur, particularly with certain systems. Approximately one in five laboratories participating in the serology exercises and one in seven participating in the genotyping exercises were classified as poor performer at one point or more during the series of exercises.
引用
收藏
页码:316 / 324
页数:9
相关论文
共 17 条
[1]  
Agildere A, 1997, BEITR INFUS, V34, P190
[2]   SENSITIVITY OF THE PLATELET IMMUNOFLUORESCENCE TEST (PIFT) AND THE MAIPA ASSAY FOR THE DETECTION OF PLATELET-REACTIVE ALLOANTIBODIES - A REPORT ON 2 UK NATIONAL PLATELET WORKSHOP EXERCISES [J].
ALLEN, DL ;
CHAPMAN, J ;
PHILLIPS, PK ;
OUWEHAND, WH .
TRANSFUSION MEDICINE, 1994, 4 (02) :157-164
[3]   Collaborative studies to establish the first World Health Organization International Standard for detection of human antibody against human platelet antigen-3a [J].
Berry, J. ;
Allen, D. ;
Porcelijn, L. ;
de Haas, M. ;
Kekomaki, R. ;
Kaplan, C. ;
Ouwehand, W. H. ;
Metcalfe, P. .
VOX SANGUINIS, 2007, 93 (04) :309-315
[4]   Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens [J].
Berry, JE ;
Murphy, CM ;
Smith, GA ;
Ranasinghe, E ;
Finberg, R ;
Walton, J ;
Brown, J ;
Navarrete, C ;
Metcalfe, P ;
Ouwehand, WH .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (03) :735-742
[5]   Microarray-based genotyping for blood groups:: comparison of gene array and 5′-nuclease assay techniques with human platelet antigen as a model [J].
Bugert, P ;
McBride, S ;
Smith, G ;
Dugrillon, A ;
Klüter, H ;
Ouwehand, WH ;
Metcalfe, P .
TRANSFUSION, 2005, 45 (05) :654-659
[6]   Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes [J].
Ertel, K ;
Al-Tawil, M ;
Santoso, S ;
Kroll, H .
TRANSFUSION, 2005, 45 (03) :366-373
[7]   Report on the 13th international society of blood transfusion platelet immunology workshop [J].
Foxcroft, Z. ;
Campbell, K. ;
Merieux, Y. ;
Urbaniak, S. ;
Brierley, M. ;
Rigal, D. ;
Ouwehand, W. H. ;
Metcalfe, P. .
VOX SANGUINIS, 2007, 93 (04) :300-305
[8]   Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia [J].
Ghevaert, Cedric ;
Campbell, Kate ;
Walton, Jill ;
Smith, Graham A. ;
Allen, Dave ;
Williamson, Lorna M. ;
Ouwehand, Willem H. ;
Ranasinghe, Edmund .
TRANSFUSION, 2007, 47 (05) :901-910
[9]   Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays [J].
Harrison, CR ;
Curtis, BR ;
McFarland, JG ;
Huff, RW ;
Aster, RH .
TRANSFUSION, 2003, 43 (10) :1398-1402
[10]   External quality assurance of DNA testing for thrombophilia mutations [J].
Hertzberg, M ;
Neville, S ;
Favaloro, E ;
McDonald, D .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (02) :189-193